Core Scientific Inc vs Moderna, Inc. — how do they compare? Core Scientific Inc trades at $21.51 (market cap $6.35B), while Moderna, Inc. trades at $60.3 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 3.8× Core Scientific Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| CORZ | MRNA | |
|---|---|---|
Market Cap | $6.35B | $24.18B |
Sector | Technology | Health |
52-Week High | $29.16 | $81.80 |
52-Week Low | $13.55 | $22.36 |
Enterprise Value | $8.88B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →